Publication | Closed Access

Novel anti-cancer agent myrtucommulone-A and thymoquinone abrogate epithelial–mesenchymal transition in cancer cells mainly through the inhibition of PI3K/AKT signalling axis

Tumor BiologyOncologyOncogenic AgentMedicineTumor ImmunityCancer Cell BiologyNovel Anti-cancer AgentEpithelial-mesenchymal InteractionsImmunotherapeuticsAnti-cancer AgentCancer CellsRadiation OncologyCancer BiologyCell BiologyCancer Research